Improving survival rates of young adult cancer
The survival rate of children with cancer has greatly improved over the past 40 years. This is largely due to the participation of patients in clinical research trials. Unfortunately, in the United States only 10 percent of patients ages 15-19 and only 1-2 percent of the patients ages 20-39 enroll in clinical trials. At Children's Mercy we want to help patients improve the outcomes of AYA cancer patients by offering the opportunity for AYA patients to participate in clinical trials. Physicians, nurse practitioners, and research coordinators work together to find clinical research trials that are available for our patients. Enrolling in a trial may not be the best option for every patient and we work closely with the patient and family to evaluate the best possibilities for the individual patients needs.
We have several different types of trials available:
- Trials that look at how we can help support patients during their diagnosis and treatment of cancer.
- Trials open that look at different treatments for cancer or blood disorders. These include trials looking at newly available drugs.
- Trials that look at how we can decrease the side effects of the medications we use to treat cancer.
Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation at Children’s Mercy Kansas City provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease, hemophilia and other blood disorders, with survival rates frequently above national averages.
Our commitment to clinical research and innovation has helped us earn recognition as one of the top cancer programs for kids in the nation by U.S. News and World Report. Children’s Mercy also has received accreditation from the American College of Surgeons Commission on Cancer and the Foundation for Accreditation of Cellular Therapy.